Net Cash Provided by (Used in) Financing Activities of NAVIDEA BIOPHARMACEUTICALS, INC. from 31 Dec 2010 to 31 Mar 2023

Taxonomy & unit: us-gaap: USD
Description: Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary: NAVIDEA BIOPHARMACEUTICALS, INC. quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2010 to 31 Mar 2023.
NAVIDEA BIOPHARMACEUTICALS, INC. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2023 was $200,539, a 41% increase year-over-year.
NAVIDEA BIOPHARMACEUTICALS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $7,141,914, a 41% decline from 2021.
NAVIDEA BIOPHARMACEUTICALS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $12,107,949, a 19% increase from 2020.
NAVIDEA BIOPHARMACEUTICALS, INC. annual Net Cash Provided by (Used in) Financing Activities for 2020 was $10,209,957, a 66% increase from 2019.
Source SEC data: View on sec.gov

Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)

Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

Net Cash Provided by (Used in) Financing Activities, Annual (USD)

Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

NAVIDEA BIOPHARMACEUTICALS, INC. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q1 2023	$200,539	+$138,914	+41%	01 Jan 2023	31 Mar 2023	10-Q	11 May 2023	2023	Q1
Q1 2022	$339,453	-$8,306,283	-104%	01 Jan 2022	31 Mar 2022	10-Q	11 May 2023	2023	Q1
Q1 2021	$7,966,830	+$7,396,866	+1298%	01 Jan 2021	31 Mar 2021	10-Q	16 May 2022	2022	Q1
Q1 2020	$569,964	+$636,940		01 Jan 2020	31 Mar 2020	10-Q	13 May 2021	2021	Q1
Q1 2019	$66,976	+$51,161	+43%	01 Jan 2019	31 Mar 2019	10-Q	15 May 2020	2020	Q1
Q1 2018	$118,137	+$60,640,567	+100%	01 Jan 2018	31 Mar 2018	10-Q	09 May 2019	2019	Q1
Q1 2017	$60,758,704			01 Jan 2017	31 Mar 2017	10-Q	09 May 2018	2018	Q1
Q1 2015	$3,499,728	+$267,265	+8.3%	01 Jan 2015	31 Mar 2015	10-Q	11 May 2015	2015	Q1
Q1 2014	$3,232,463	-$5,247,347	-62%	01 Jan 2014	31 Mar 2014	10-Q	11 May 2015	2015	Q1
Q1 2013	$8,479,810	+$8,487,197		01 Jan 2013	31 Mar 2013	10-Q	09 May 2014	2014	Q1
Q1 2012	$7,387^*	-$5,142,183		01 Jan 2012	31 Mar 2012	10-Q	10 May 2013	2013	Q1
Q1 2011	$5,134,796			01 Jan 2011	31 Mar 2011	10-Q	10 May 2012	2012	Q1

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2022	$7,141,914	-$4,966,035	-41%	01 Jan 2022	31 Dec 2022	10-K	27 Mar 2023	2022	FY
2021	$12,107,949	+$1,897,992	+19%	01 Jan 2021	31 Dec 2021	10-K	27 Mar 2023	2022	FY
2020	$10,209,957	+$4,054,374	+66%	01 Jan 2020	31 Dec 2020	10-K	28 Mar 2022	2021	FY
2019	$6,155,583	+$10,703,956		01 Jan 2019	31 Dec 2019	10-K	26 Mar 2021	2020	FY
2018	$4,548,373	+$56,447,050	+93%	01 Jan 2018	31 Dec 2018	10-K	18 Mar 2020	2019	FY
2017	$60,995,423	-$51,850,932	-567%	01 Jan 2017	31 Dec 2017	10-K	15 Mar 2019	2018	FY
2016	$9,144,491	-$29,935,603	-144%	01 Jan 2016	31 Dec 2016	10-K	15 Mar 2018	2017	FY
2015	$20,791,112	+$17,599,417	+551%	01 Jan 2015	31 Dec 2015	10-K	15 Mar 2018	2017	FY
2014	$3,191,695	-$57,533,209	-95%	01 Jan 2014	31 Dec 2014	8-K	15 Dec 2017	2016	FY
2013	$60,724,904	+$55,655,217	+1098%	01 Jan 2013	31 Dec 2013	10-K	16 Mar 2015	2014	FY
2012	$5,069,687	-$6,005,555	-54%	01 Jan 2012	31 Dec 2012	10-K	16 Mar 2015	2014	FY
2011	$11,075,242	+$4,726,070	+74%	01 Jan 2011	31 Dec 2011	10-K	14 Mar 2014	2013	FY
2010	$6,349,172			01 Jan 2010	31 Dec 2010	10-K/A	21 Mar 2013	2012	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.